109 related articles for article (PubMed ID: 1800016)
21. A randomized study of alfacalcidol in the refractory myelodysplastic anaemias. A Japanese cooperative study.
Yoshida Y; Oguma S; Uchino H; Maekawa T; Nomura T
Int J Clin Pharmacol Res; 1993; 13(1):21-7. PubMed ID: 8509233
[TBL] [Abstract][Full Text] [Related]
22. Treatment of psoriasis vulgaris by oral administration of 1 alpha-hydroxyvitamin D3--open-design study.
Morimoto S; Yoshikawa K; Kozuka T; Kitano Y; Imanaka S; Fukuo K; Koh E; Onishi T; Kumahara Y
Calcif Tissue Int; 1986 Sep; 39(3):209-12. PubMed ID: 3093033
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of recombinant human granulocyte-macrophage colony-stimulating factor in myelodysplastic syndrome and aplastic anemia.
Takahashi M; Yoshida Y; Kaku K; Masaoka T; Moriyama Y; Nakanishi S; Kaneko T; Shibata A; Miwa S
Acta Haematol; 1993; 89(4):189-94. PubMed ID: 8212999
[TBL] [Abstract][Full Text] [Related]
24. Overuse of granulocyte colony-stimulating factor in acute myeloid leukemia, aplastic anemia and myelodysplastic syndrome.
Shinohara K
Intern Med; 2000 Jan; 39(1):82. PubMed ID: 10674858
[No Abstract] [Full Text] [Related]
25. 1 alpha-hydroxyvitamin D3 plus 25-hydroxyvitamin D3 reduces parturient paresis in dairy cows fed high dietary calcium.
Hodnett DW; Jorgensen NA; Deluca HF
J Dairy Sci; 1992 Feb; 75(2):485-91. PubMed ID: 1560144
[TBL] [Abstract][Full Text] [Related]
26. 1 alpha-hydroxyvitamin D3 in intestinal calcium malabsorption. A pilot study.
Hylander E; Jarnum S
Scand J Gastroenterol; 1980; 15(4):443-8. PubMed ID: 7433906
[TBL] [Abstract][Full Text] [Related]
27. [Pathogenesis and treatment of myelodysplastic syndromes and hypoplastic anemia].
Gavrilov OK; Terent'reva OV
Klin Med (Mosk); 1990 Aug; 68(8):23-6. PubMed ID: 2084365
[No Abstract] [Full Text] [Related]
28. Hypoparathyroidism--a long-term follow-up experience with 1 alpha-vitamin D3 therapy.
Halabe A; Arie R; Mimran D; Samuel R; Liberman UA
Clin Endocrinol (Oxf); 1994 Mar; 40(3):303-7. PubMed ID: 8187292
[TBL] [Abstract][Full Text] [Related]
29. Effect of 1 alpha-hydroxycholecalciferol on psoriasis vulgaris: a pilot study.
Takamoto S; Onishi T; Morimoto S; Imanaka S; Yukawa S; Kozuka T; Kitano Y; Seino Y; Kumahara Y
Calcif Tissue Int; 1986 Dec; 39(6):360-4. PubMed ID: 3100000
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of myelodysplastic syndrome with alfacalcidol].
Tagawa M; Ito H; Kuriyama K; Tomonaga M; Ichimaru M
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3160-2. PubMed ID: 3674901
[No Abstract] [Full Text] [Related]
31. 1,25-dihydroxyvitamin D3 and 1, alpha-hydroxyvitamin D3 in children: biologic and therapeutic effects in nutritional rickets and different types of vitamin D resistance.
Balsan S; Garabedian M; Sorgniard R; Holick MF; Deluca HF
Pediatr Res; 1975 Jul; 9(7):586-93. PubMed ID: 169507
[TBL] [Abstract][Full Text] [Related]
32. Myelodysplastic syndrome and aplastic anemia--diagnostic and conceptual uncertainties.
Barrett J
Leuk Res; 2000 Jul; 24(7):595-6. PubMed ID: 10867134
[No Abstract] [Full Text] [Related]
33. Rickets with alopecia-remission following a course of 1-alpha-hydroxy vitamin D3 therapy.
Manandhar DS; Sarkawi S; Hunt MC
Eur J Pediatr; 1989 Aug; 148(8):761-3. PubMed ID: 2551693
[TBL] [Abstract][Full Text] [Related]
34. Vitamin D supplementation for prevention of mortality in adults.
Bjelakovic G; Gluud LL; Nikolova D; Whitfield K; Wetterslev J; Simonetti RG; Bjelakovic M; Gluud C
Cochrane Database Syst Rev; 2014 Jan; (1):CD007470. PubMed ID: 24414552
[TBL] [Abstract][Full Text] [Related]
35. [Comparative antirachitic activity of 1,25-dihydroxyvitamin D3 and 1 alpha-hydroxyvitamin D3 in the chick].
Babarykin DA; Rozental' RL; Valinietse MIu; Bauman VK
Vopr Med Khim; 1982; 28(2):64-6. PubMed ID: 6896250
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of active vitamins D3, 1 alpha-hydroxyvitamin D3 and 1 alpha, 25-dihydroxyvitamin D3 in patients on chronic hemodialysis.
Kimura Y; Nakayama M; Kuriyama S; Watanabe S; Kawaguchi Y; Sakai O
Clin Nephrol; 1991 Feb; 35(2):72-7. PubMed ID: 2019017
[TBL] [Abstract][Full Text] [Related]
37. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
[TBL] [Abstract][Full Text] [Related]
38. A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease.
Tarrass F; Yazidi A; Sif H; Zamd M; Benghanem MG; Ramdani B
Clin Nephrol; 2006 Jun; 65(6):415-8. PubMed ID: 16792136
[TBL] [Abstract][Full Text] [Related]
39. A low dose regime of 1 alpha hydroxyvitamin D3 in the management of senile osteoporosis: a pilot study.
Cohen HN; Farrah D; Fogelman I; Goll CC; Beastall GH; McIntosh WB; Fletcher M; Boyle IT
Clin Endocrinol (Oxf); 1980 Jun; 12(6):537-42. PubMed ID: 7398099
[TBL] [Abstract][Full Text] [Related]
40. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia.
Bessho M; Jinnai I; Matsuda A; Saito M; Hirashima K
Int J Cell Cloning; 1990 Nov; 8(6):445-58. PubMed ID: 2273298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
